Johnson & Johnson (JNJ) Q2 FY2026 Financial Statements: Revenue $25.31B, Net income $5.53B
More for Johnson & Johnson: Company index · 10-K and 10-Q summary · 8-K filings and events
PeriodQ2 FY2026
Published
Johnson & Johnson reported $25.31 billion in sales for Q2 FY2026, the quarter ended June 28, 2026, up 6.6% from $23.74 billion a year earlier and a quarterly sales record for the company. Net income was $5.53 billion, essentially unchanged from $5.54 billion, and diluted EPS was $2.27 against $2.29, with the sales growth absorbed by a higher effective tax rate, a new supply chain restructuring program and costs of the planned Orthopaedics separation. Innovative Medicine sales of $16.38 billion drove the quarter as the oncology franchise led by DARZALEX, together with TREMFYA in immunology, more than covered continued STELARA biosimilar erosion, while MedTech contributed $8.93 billion.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $25,310,000,000 | up 6.6% |
| Net income | $5,534,000,000 | down 0.1% |
| Diluted EPS | $2.27 | down 0.9% |
| Innovative Medicine sales | $16,384,000,000 | up 7.8% |
| MedTech sales | $8,926,000,000 | up 4.5% |
About this file
| Ticker | JNJ |
|---|---|
| CIK | 0000200406 |
| Company | Johnson & Johnson |
| Business type | pharmaceutical and medical technology (standard industrial/consumer template, extended with segment revenue, segment pre-tax income and R&D expense) |
| Schema rationale | Johnson & Johnson is a two-segment healthcare products company (Innovative Medicine and MedTech). The standard revenue / cost of products sold / gross profit / net income / EPS / balance-sheet / cash-flow template fits it directly. Because research and development and the two-segment split are central to how the business earns money, segment sales, segment pre-tax income and R&D expense are reported alongside the standard lines. Johnson & Johnson does not present an 'operating income' subtotal on the face of its statement of earnings, so an operating income figure is derived here (gross profit less selling, marketing and administrative expenses, research and development expense, in-process research and development impairments and restructuring) and is labeled as derived wherever it appears. |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual dollars (not millions); per-share figures are in actual dollars per share; share counts are actual shares |
| Fiscal calendar note | Johnson & Johnson uses a 52/53-week fiscal year ending on the Sunday nearest to December 31. Fiscal 2025 ended December 28, 2025; fiscal 2024 ended December 29, 2024; fiscal 2023 ended December 31, 2023. The fiscal 2026 second quarter ended June 28, 2026. |
JNJ annual income statement, balance sheet and cash flow
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Fiscal year | 2025 | 2024 | 2023 |
| Period start | 2024-12-30 | 2024-01-01 | 2023-01-02 |
| Period end | 2025-12-28 | 2024-12-29 | 2023-12-31 |
| Period label | Fiscal year 2025 (52 weeks ended December 28, 2025) | Fiscal year 2024 (52 weeks ended December 29, 2024) | Fiscal year 2023 (53 weeks ended December 31, 2023) |
| Source accession | 0000200406-26-000016 | 0000200406-26-000016 | 0000200406-26-000016 |
| Source form | 10-K filed 2026-02-11 | 10-K filed 2026-02-11 (comparative columns) | 10-K filed 2026-02-11 (comparative columns; balance sheet not presented for this year) |
| Income statement | |||
| Revenue | 94,193,000,000 | 88,821,000,000 | 85,159,000,000 |
| Cost of products sold | 30,256,000,000 | 27,471,000,000 | 26,553,000,000 |
| Gross profit | 63,937,000,000 | 61,350,000,000 | 58,606,000,000 |
| Gross margin % | 67.9% | 69.1% | 68.8% |
| Selling marketing and administrative expenses | 23,676,000,000 | 22,869,000,000 | 21,512,000,000 |
| Research and development expense | 14,665,000,000 | 17,232,000,000 | 15,085,000,000 |
| In process rd impairments | 81,000,000 | 211,000,000 | 313,000,000 |
| Restructuring | 228,000,000 | 234,000,000 | 489,000,000 |
| Operating income derived | 25,287,000,000 | 20,804,000,000 | 21,207,000,000 |
| Interest income | 1,056,000,000 | 1,332,000,000 | 1,261,000,000 |
| Interest expense net of capitalized | 971,000,000 | 755,000,000 | 772,000,000 |
| Other income expense net | -7,209,000,000 | 4,694,000,000 | 6,634,000,000 |
| Pretax income | 32,581,000,000 | 16,687,000,000 | 15,062,000,000 |
| Provision for taxes on income | 5,777,000,000 | 2,621,000,000 | 1,736,000,000 |
| Effective tax rate % | 17.7% | 15.7% | 11.5% |
| Net earnings continuing operations | 26,804,000,000 | 14,066,000,000 | 13,326,000,000 |
| Net earnings discontinued operations | 0 | 0 | 21,827,000,000 |
| Net income | 26,804,000,000 | 14,066,000,000 | 35,153,000,000 |
| EPS basic | 11.13 | 5.84 | 13.88 |
| EPS diluted | 11.03 | 5.79 | 13.72 |
| Weighted average shares basic | 2,407,400,000 | 2,407,300,000 | 2,533,500,000 |
| Weighted average shares diluted | 2,429,400,000 | 2,429,400,000 | 2,560,400,000 |
| Dividends paid per share | 5.14 | 4.91 | 4.7 |
| EPS basic continuing operations | 5.26 | ||
| EPS diluted continuing operations | 5.2 | ||
| Segments | |||
| Innovative medicine | |||
| Sales to customers | 60,401,000,000 | 56,964,000,000 | 54,759,000,000 |
| Cost of products sold | 15,646,000,000 | 14,036,000,000 | 13,715,000,000 |
| Selling marketing and administrative | 11,375,000,000 | 10,906,000,000 | 9,842,000,000 |
| Research and development expense | 11,827,000,000 | 13,529,000,000 | 11,963,000,000 |
| Other segment items | -713,000,000 | -426,000,000 | 993,000,000 |
| Segment income before tax | 22,266,000,000 | 18,919,000,000 | 18,246,000,000 |
| Identifiable assets | 78,057,000,000 | 57,070,000,000 | |
| Additions to ppe | 2,076,000,000 | 1,710,000,000 | 1,653,000,000 |
| Depreciation and amortization | 3,772,000,000 | 3,760,000,000 | 3,847,000,000 |
| Medtech | |||
| Sales to customers | 33,792,000,000 | 31,857,000,000 | 30,400,000,000 |
| Cost of products sold | 14,549,000,000 | 13,345,000,000 | 12,722,000,000 |
| Selling marketing and administrative | 11,354,000,000 | 10,812,000,000 | 10,476,000,000 |
| Research and development expense | 2,838,000,000 | 3,703,000,000 | 3,122,000,000 |
| Other segment items | 938,000,000 | 257,000,000 | -589,000,000 |
| Segment income before tax | 4,113,000,000 | 3,740,000,000 | 4,669,000,000 |
| Identifiable assets | 86,482,000,000 | 84,322,000,000 | |
| Additions to ppe | 2,501,000,000 | 2,443,000,000 | 2,372,000,000 |
| Depreciation and amortization | 3,490,000,000 | 3,237,000,000 | 2,943,000,000 |
| Total segment income before tax | 26,379,000,000 | 22,659,000,000 | 22,915,000,000 |
| Income expense not allocated to segments | -6,202,000,000 | 5,972,000,000 | 7,853,000,000 |
| Geography | |||
| United states sales | 53,752,000,000 | 50,302,000,000 | 46,444,000,000 |
| International sales | 40,441,000,000 | 38,519,000,000 | 38,715,000,000 |
| Europe sales | 21,535,000,000 | 20,212,000,000 | 20,410,000,000 |
| Western hemisphere excluding US sales | 4,875,000,000 | 4,714,000,000 | 4,549,000,000 |
| Asia pacific africa sales | 14,031,000,000 | 13,593,000,000 | 13,756,000,000 |
| Balance sheet | |||
| Cash and cash equivalents | 19,709,000,000 | 24,105,000,000 | |
| Marketable securities | 393,000,000 | 417,000,000 | |
| Cash and marketable securities | 20,102,000,000 | 24,522,000,000 | |
| Accounts receivable trade net | 17,178,000,000 | 14,842,000,000 | |
| Inventories | 14,191,000,000 | 12,444,000,000 | |
| Prepaid expenses and other receivables | 4,153,000,000 | 4,085,000,000 | |
| Total current assets | 55,624,000,000 | 55,893,000,000 | |
| Property plant and equipment net | 23,169,000,000 | 20,518,000,000 | |
| Intangible assets net | 50,403,000,000 | 37,618,000,000 | |
| Goodwill | 48,772,000,000 | 44,200,000,000 | |
| Deferred taxes on income asset | 6,874,000,000 | 10,461,000,000 | |
| Other assets | 14,368,000,000 | 11,414,000,000 | |
| Total assets | 199,210,000,000 | 180,104,000,000 | |
| Loans and notes payable current | 8,495,000,000 | 5,983,000,000 | |
| Accounts payable | 11,991,000,000 | 10,311,000,000 | |
| Accrued liabilities | 8,594,000,000 | 8,549,000,000 | |
| Accrued rebates returns and promotions | 19,124,000,000 | 17,580,000,000 | |
| Accrued compensation and employee related obligations | 4,534,000,000 | 4,126,000,000 | |
| Accrued taxes on income | 1,388,000,000 | 3,772,000,000 | |
| Total current liabilities | 54,126,000,000 | 50,321,000,000 | |
| Long term debt | 39,438,000,000 | 30,651,000,000 | |
| Deferred taxes on income liability | 6,791,000,000 | 2,448,000,000 | |
| Employee related obligations | 6,957,000,000 | 7,255,000,000 | |
| Long term taxes payable | 486,000,000 | 390,000,000 | |
| Other liabilities | 9,868,000,000 | 17,549,000,000 | |
| Total liabilities | 117,666,000,000 | 108,614,000,000 | |
| Total debt derived | 47,933,000,000 | 36,634,000,000 | |
| Net debt derived | 27,831,000,000 | 12,112,000,000 | |
| Total shareholders equity | 81,544,000,000 | 71,490,000,000 | |
| Common shares issued | 3,119,843,000 | 3,119,843,000 | |
| Treasury shares | 711,904,000 | 712,921,000 | |
| Shares outstanding derived | 2,407,939,000 | 2,406,922,000 | |
| Book value per share derived | 33.86 | 29.7 | |
| Cash flow | |||
| Net earnings | 26,804,000,000 | 14,066,000,000 | 35,153,000,000 |
| Depreciation and amortization | 7,503,000,000 | 7,339,000,000 | 7,486,000,000 |
| Stock based compensation | 1,354,000,000 | 1,176,000,000 | 1,162,000,000 |
| Deferred tax provision | 1,538,000,000 | -2,183,000,000 | -4,194,000,000 |
| Operating cash flow | 24,530,000,000 | 24,266,000,000 | 22,791,000,000 |
| Capital expenditures | 4,832,000,000 | 4,424,000,000 | 4,543,000,000 |
| Free cash flow derived | 19,698,000,000 | 19,842,000,000 | 18,248,000,000 |
| Acquisitions net of cash acquired | 17,541,000,000 | 15,146,000,000 | 0 |
| Acquired ipr and d and milestones | 385,000,000 | 1,783,000,000 | 470,000,000 |
| Investing cash flow | -23,588,000,000 | -18,599,000,000 | 878,000,000 |
| Dividends paid | 12,381,000,000 | 11,823,000,000 | 11,770,000,000 |
| Share repurchases | 5,953,000,000 | 2,432,000,000 | 5,054,000,000 |
| Financing cash flow | -5,539,000,000 | -3,132,000,000 | -15,825,000,000 |
| Cash paid for interest | 1,977,000,000 | 1,990,000,000 | 1,836,000,000 |
| Cash paid for income taxes | 6,539,000,000 | 6,714,000,000 | 8,574,000,000 |
| Gain on kenvue separation | -20,984,000,000 | ||
| Note | The 10-K states that amounts presented for 2023 in the statement of cash flows have not been recast to exclude discontinued operations, so the fiscal 2023 cash flow figures include the Consumer Health business separated as Kenvue. | ||
| Balance sheet note | The FY2025 10-K balance sheet presents only December 28, 2025 and December 29, 2024, so no fiscal 2023 balance sheet is reported here. | ||
JNJ quarterly income statement, balance sheet and cash flow
| 2026-06-28 | 2025-06-29 | 2026-03-29 | |
|---|---|---|---|
| Period label | Fiscal second quarter 2026 (13 weeks ended June 28, 2026) | Fiscal second quarter 2025 (13 weeks ended June 29, 2025), prior-year comparative | Fiscal first quarter 2026 (13 weeks ended March 29, 2026), derived |
| Period type | quarter | quarter | quarter_derived |
| Period start | 2026-03-30 | 2025-03-31 | 2025-12-29 |
| Period end | 2026-06-28 | 2025-06-29 | 2026-03-29 |
| Source accession | 0000200406-26-000153 | 0000200406-26-000153 | 0000200406-26-000153 |
| Source form | 10-Q filed 2026-07-23 | 10-Q filed 2026-07-23 (comparative columns) | Derived by subtracting the fiscal second quarter 2026 columns from the fiscal six months 2026 columns of the 10-Q filed 2026-07-23 |
| Income statement | |||
| Revenue | 25,310,000,000 | 23,743,000,000 | 24,062,000,000 |
| Cost of products sold | 8,051,000,000 | 7,628,000,000 | 8,106,000,000 |
| Gross profit | 17,259,000,000 | 16,115,000,000 | 15,956,000,000 |
| Gross margin % | 68.2% | 67.9% | |
| Selling marketing and administrative expenses | 6,432,000,000 | 5,889,000,000 | |
| Research and development expense | 3,653,000,000 | 3,516,000,000 | 3,527,000,000 |
| Restructuring | 34,000,000 | 64,000,000 | |
| Operating income derived | 7,140,000,000 | 6,646,000,000 | |
| Interest income | 219,000,000 | 260,000,000 | |
| Interest expense net of capitalized | 281,000,000 | 308,000,000 | |
| Other income expense net | 331,000,000 | 107,000,000 | |
| Pretax income | 6,747,000,000 | 6,491,000,000 | 5,990,000,000 |
| Provision for taxes on income | 1,213,000,000 | 954,000,000 | |
| Effective tax rate % | 18.0% | 14.7% | |
| Net income | 5,534,000,000 | 5,537,000,000 | 5,235,000,000 |
| Net margin % | 21.9% | 23.3% | |
| EPS basic | 2.3 | 2.3 | |
| EPS diluted | 2.27 | 2.29 | |
| Weighted average shares basic | 2,407,400,000 | 2,406,300,000 | |
| Weighted average shares diluted | 2,440,100,000 | 2,419,100,000 | |
| Dividends paid per share | 1.34 | 1.3 | |
| Segments | |||
| Innovative medicine | |||
| Sales to customers | 16,384,000,000 | 15,202,000,000 | |
| Cost of products sold | 4,296,000,000 | 3,978,000,000 | |
| Selling marketing and administrative | 3,130,000,000 | 2,789,000,000 | |
| Research and development expense | 2,875,000,000 | 2,869,000,000 | |
| Other segment items | -166,000,000 | 14,000,000 | |
| Segment income before tax | 6,249,000,000 | 5,552,000,000 | |
| Medtech | |||
| Sales to customers | 8,926,000,000 | 8,541,000,000 | |
| Cost of products sold | 3,737,000,000 | 3,638,000,000 | |
| Selling marketing and administrative | 3,069,000,000 | 2,862,000,000 | |
| Research and development expense | 778,000,000 | 647,000,000 | |
| Other segment items | 165,000,000 | 190,000,000 | |
| Segment income before tax | 1,177,000,000 | 1,204,000,000 | |
| Total segment income before tax | 7,426,000,000 | 6,756,000,000 | |
| Income expense not allocated to segments | 679,000,000 | 265,000,000 | |
| Balance sheet | |||
| As of | 2026-06-28 | ||
| Cash and cash equivalents | 20,422,000,000 | ||
| Marketable securities | 336,000,000 | ||
| Cash and marketable securities | 20,758,000,000 | ||
| Accounts receivable trade net | 19,046,000,000 | ||
| Inventories | 15,144,000,000 | ||
| Prepaid expenses and other | 4,826,000,000 | ||
| Total current assets | 59,774,000,000 | ||
| Property plant and equipment gross | 55,518,000,000 | ||
| Accumulated depreciation | 31,936,000,000 | ||
| Property plant and equipment net | 23,582,000,000 | ||
| Intangible assets net | 48,229,000,000 | ||
| Goodwill | 48,479,000,000 | ||
| Deferred taxes on income asset | 6,728,000,000 | ||
| Other assets | 14,269,000,000 | ||
| Total assets | 201,061,000,000 | ||
| Loans and notes payable current | 11,692,000,000 | ||
| Accounts payable | 9,223,000,000 | ||
| Accrued liabilities | 9,464,000,000 | ||
| Accrued rebates returns and promotions | 19,990,000,000 | ||
| Accrued compensation and employee related obligations | 3,475,000,000 | ||
| Accrued taxes on income | 1,051,000,000 | ||
| Total current liabilities | 54,895,000,000 | ||
| Long term debt | 37,344,000,000 | ||
| Deferred taxes on income liability | 6,608,000,000 | ||
| Employee related obligations | 6,657,000,000 | ||
| Long term taxes payable | 485,000,000 | ||
| Other liabilities | 10,101,000,000 | ||
| Total liabilities | 116,090,000,000 | ||
| Total debt derived | 49,036,000,000 | ||
| Net debt derived | 28,278,000,000 | ||
| Total shareholders equity | 84,971,000,000 | ||
| Common shares issued | 3,119,843,000 | ||
| Treasury shares | 711,615,000 | ||
| Shares outstanding derived | 2,408,228,000 | ||
| Shares outstanding cover page | 2,409,898,597 | ||
| Shares outstanding cover page date | 2026-07-17 | ||
| Book value per share derived | 35.28 | ||
| Note | These first-quarter figures are arithmetic differences between the six-month and second-quarter columns of the FY2026 second-quarter 10-Q, not figures presented directly on the face of that filing. | ||
JNJ year-to-date income statement and cash flow
| 2026-06-28 | |
|---|---|
| Period label | Fiscal six months 2026 (26 weeks ended June 28, 2026) |
| Period type | year_to_date |
| Period start | 2025-12-29 |
| Period end | 2026-06-28 |
| Source accession | 0000200406-26-000153 |
| Source form | 10-Q filed 2026-07-23 |
| Income statement | |
| Revenue | 49,372,000,000 |
| Cost of products sold | 16,157,000,000 |
| Gross profit | 33,215,000,000 |
| Gross margin % | 67.3% |
| Selling marketing and administrative expenses | 12,466,000,000 |
| Research and development expense | 7,180,000,000 |
| In process rd impairments | 36,000,000 |
| Restructuring | 66,000,000 |
| Operating income derived | 13,467,000,000 |
| Interest income | 448,000,000 |
| Interest expense net of capitalized | 553,000,000 |
| Other income expense net | 625,000,000 |
| Pretax income | 12,737,000,000 |
| Provision for taxes on income | 1,968,000,000 |
| Effective tax rate % | 15.5% |
| Net income | 10,769,000,000 |
| Net margin % | 21.8% |
| EPS basic | 4.47 |
| EPS diluted | 4.41 |
| Weighted average shares basic | 2,408,100,000 |
| Weighted average shares diluted | 2,443,900,000 |
| Dividends paid per share | 2.64 |
| Segments | |
| Innovative medicine | |
| Sales to customers | 31,810,000,000 |
| Cost of products sold | 8,686,000,000 |
| Selling marketing and administrative | 6,048,000,000 |
| Research and development expense | 5,688,000,000 |
| Other segment items | -178,000,000 |
| Segment income before tax | 11,566,000,000 |
| Medtech | |
| Sales to customers | 17,562,000,000 |
| Cost of products sold | 7,438,000,000 |
| Selling marketing and administrative | 5,975,000,000 |
| Research and development expense | 1,492,000,000 |
| Other segment items | 241,000,000 |
| Segment income before tax | 2,416,000,000 |
| Total segment income before tax | 13,982,000,000 |
| Income expense not allocated to segments | 1,245,000,000 |
| Cash flow | |
| Net earnings | 10,769,000,000 |
| Depreciation and amortization | 3,963,000,000 |
| Stock based compensation | 758,000,000 |
| Deferred tax provision | -320,000,000 |
| Operating cash flow | 11,130,000,000 |
| Capital expenditures | 2,370,000,000 |
| Free cash flow derived | 8,760,000,000 |
| Acquisitions net of cash acquired | 263,000,000 |
| Investing cash flow | -2,150,000,000 |
| Dividends paid | 6,358,000,000 |
| Share repurchases | 4,249,000,000 |
| Financing cash flow | -8,247,000,000 |
| Cash and cash equivalents end of period | 20,422,000,000 |
| Prior year comparative | |
| Period label | Fiscal six months 2025 (26 weeks ended June 29, 2025), prior-year comparative |
| Period type | year_to_date |
| Period start | 2024-12-30 |
| Period end | 2025-06-29 |
| Source accession | 0000200406-26-000153 |
| Source form | 10-Q filed 2026-07-23 (comparative columns) |
| Income statement | |
| Revenue | 45,636,000,000 |
| Cost of products sold | 14,985,000,000 |
| Gross profit | 30,651,000,000 |
| Gross margin % | 67.2% |
| Selling marketing and administrative expenses | 11,001,000,000 |
| Research and development expense | 6,741,000,000 |
| In process rd impairments | 0 |
| Restructuring | 81,000,000 |
| Operating income derived | 12,828,000,000 |
| Interest income | 592,000,000 |
| Interest expense net of capitalized | 512,000,000 |
| Other income expense net | -7,214,000,000 |
| Pretax income | 20,122,000,000 |
| Provision for taxes on income | 3,586,000,000 |
| Effective tax rate % | 17.8% |
| Net income | 16,536,000,000 |
| Net margin % | 36.2% |
| EPS basic | 6.87 |
| EPS diluted | 6.82 |
| Weighted average shares basic | 2,406,700,000 |
| Weighted average shares diluted | 2,423,300,000 |
| Dividends paid per share | 2.54 |
| Segments | |
| Innovative medicine | |
| Sales to customers | 29,075,000,000 |
| Cost of products sold | 7,998,000,000 |
| Selling marketing and administrative | 5,050,000,000 |
| Research and development expense | 5,417,000,000 |
| Other segment items | -152,000,000 |
| Segment income before tax | 10,762,000,000 |
| Medtech | |
| Sales to customers | 16,561,000,000 |
| Cost of products sold | 6,964,000,000 |
| Selling marketing and administrative | 5,518,000,000 |
| Research and development expense | 1,324,000,000 |
| Other segment items | 130,000,000 |
| Segment income before tax | 2,625,000,000 |
| Total segment income before tax | 13,387,000,000 |
| Income expense not allocated to segments | -6,735,000,000 |
| Cash flow | |
| Net earnings | 16,536,000,000 |
| Depreciation and amortization | 3,715,000,000 |
| Stock based compensation | 698,000,000 |
| Deferred tax provision | 2,997,000,000 |
| Operating cash flow | 8,052,000,000 |
| Capital expenditures | 1,838,000,000 |
| Free cash flow derived | 6,214,000,000 |
| Acquisitions net of cash acquired | 14,458,000,000 |
| Investing cash flow | -18,561,000,000 |
| Dividends paid | 6,118,000,000 |
| Share repurchases | 2,127,000,000 |
| Financing cash flow | 4,757,000,000 |
| Cash and cash equivalents end of period | 18,577,000,000 |
JNJ trailing twelve month income statement and cash flow
| 2026-06-28 | |
|---|---|
| Period label | Trailing twelve months ended June 28, 2026 |
| Period end | 2026-06-28 |
| Method | Fiscal year 2025 (accession 0000200406-26-000016) plus fiscal six months 2026 less fiscal six months 2025 (both from accession 0000200406-26-000153) |
| Revenue | 97,929,000,000 |
| Net income | 21,037,000,000 |
| Research and development expense | 15,104,000,000 |
| Operating cash flow | 27,608,000,000 |
| Capital expenditures | 5,364,000,000 |
| Free cash flow | 22,244,000,000 |
| Dividends paid | 12,621,000,000 |
| Share repurchases | 8,075,000,000 |
| EPS diluted approx | 8.62 |
| EPS diluted note | Trailing-twelve-month diluted EPS computed as fiscal 2025 diluted EPS of $11.03 plus fiscal six months 2026 diluted EPS of $4.41 less fiscal six months 2025 diluted EPS of $6.82. Because the weighted average diluted share count differs across those periods, this is an approximation rather than a figure presented in any filing. |
Adjustments
| Value | |
|---|---|
| Splits applied | none |
| Splits note | No stock splits apply to the periods reported here, so no per-share figure required split adjustment. |
| ADR ratio | n/a |
| FX | None. Johnson & Johnson reports in U.S. dollars, so no currency conversion was applied. |
Notes
- All figures are stated in actual U.S. dollars. The filings present dollar amounts in millions and weighted average share counts in millions; those have been multiplied out here. Balance-sheet share counts (shares issued and treasury shares) are already stated as full share counts in the filings and were carried across unchanged.
- Annual coverage reflects what the FY2025 10-K (accession 0000200406-26-000016) actually presents: three years on the statements of earnings, cash flows and segment tables (fiscal 2025, 2024 and 2023), but only two years on the balance sheet (December 28, 2025 and December 29, 2024). No fiscal 2023 balance sheet is reported for that reason.
- Johnson & Johnson does not present an operating income subtotal on the face of its consolidated statements of earnings. The 'operating_income_derived' figures here are computed as gross profit less selling, marketing and administrative expenses, research and development expense, in-process research and development impairments and restructuring. Each derived figure reconciles exactly to the reported pre-tax earnings once interest income, interest expense and other (income) expense, net are added back.
- Fiscal 2023 net earnings of $35.153 billion include $21.827 billion of net earnings from discontinued operations, essentially the separation of the Consumer Health business as Kenvue, including a $20.984 billion gain on that separation. Continuing-operations net earnings for fiscal 2023 were $13.326 billion and continuing-operations diluted earnings per share were $5.20. Comparisons of fiscal 2023 total net income to later years are not like-for-like. The 10-K also states that fiscal 2023 cash flow statement amounts have not been recast to exclude discontinued operations.
- Fiscal 2025 pre-tax earnings and net earnings are flattered by $7.209 billion of net other income, the large majority of which arose in the first six months of fiscal 2025 (the 10-Q shows $7.214 billion of net other income in the fiscal six months ended June 29, 2025). This is why fiscal six months 2025 net earnings of $16.536 billion exceed fiscal six months 2026 net earnings of $10.769 billion despite higher 2026 sales. Fiscal 2024 pre-tax earnings were correspondingly depressed by $4.694 billion of net other expense and by elevated research and development expense of $17.232 billion, which included large acquired in-process research and development charges.
- Research and development expense on the face of the statement of earnings ($14.665 billion in fiscal 2025) is reported by Johnson & Johnson under a tag that excludes acquired in-process research and development costs. In the SEC's XBRL company facts, the plain 'ResearchAndDevelopmentExpense' concept is populated instead with the much smaller charge for acquired in-process research and development ($109 million in fiscal 2025, $1.841 billion in fiscal 2024, $483 million in fiscal 2023). The income statement line as printed in the filing is what is reported here.
- Total debt is not a line item in the filings; it is derived here as loans and notes payable plus long-term debt. Net debt is derived as total debt less cash and cash equivalents and marketable securities. Book value per share is derived as total shareholders' equity divided by shares issued less treasury shares.
- Cash dividends paid per share come from the consolidated statements of equity and management's discussion: $5.14 in fiscal 2025, $4.91 in fiscal 2024 and $4.70 in fiscal 2023. The fiscal 2025 10-K notes the dividend was increased for the 63rd consecutive year. The FY2026 second-quarter 10-Q shows $1.34 per share paid in the second quarter of 2026 and $2.64 for the six months, and discloses a further $1.34 per share quarterly dividend declared on July 15, 2026, payable September 8, 2026.
- A Form 8-K dated July 15, 2026 (accession 0000200406-26-000146) carried the fiscal second quarter 2026 earnings release. The 10-Q filed July 23, 2026 (accession 0000200406-26-000153) covers the same period and is the authoritative source used here; no figure in this file comes from the press release.
- The FY2026 second-quarter 10-Q discloses that in October 2025 the Company announced its intention to separate its Orthopaedics business, targeting completion within 18 to 24 months of that announcement. That business is still consolidated in every figure reported here.
- Segment 'other segment items' as reported by the Company can be negative, which reduces segment expense and raises segment income before tax. Segment income before tax for the two segments does not sum to consolidated pre-tax earnings; the difference is the income and expense the Company does not allocate to segments, reported separately here.
Uncertainties
- Operating income is a derived figure, not a subtotal the Company reports. A reader who prefers to exclude restructuring, in-process research and development impairments, or intangible amortization from operating income would arrive at a different number. The components are all reported here so the derivation can be recomputed.
- Trailing-twelve-month diluted earnings per share of about $8.62 is an approximation built from three periods with different weighted average diluted share counts. Trailing-twelve-month revenue, net income and cash flow figures are exact period arithmetic and carry no such caveat.
- The fiscal first quarter 2026 figures are derived by subtracting the second-quarter column from the six-month column of the FY2026 second-quarter 10-Q. They are arithmetically sound for the lines shown but were not presented as a first-quarter column in that filing; only revenue, cost of products sold, gross profit, research and development expense, pre-tax income and net income are reported for that period here.
- Balance-sheet 'shares outstanding' is derived as shares issued less treasury shares at the balance sheet date (2,408,228,000 at June 28, 2026). The cover page of the same 10-Q reports 2,409,898,597 shares outstanding as of July 17, 2026, a later date; both are shown so the difference is visible.
- Fiscal 2023 identifiable assets by segment are not reported here because the segment identifiable-assets table in the FY2025 10-K presents only fiscal 2025 and fiscal 2024.
- Effective tax rates shown are computed as provision for taxes on income divided by earnings before provision for taxes on income, and are not the rates the Company discusses in its tax note, which reconcile to the U.S. statutory rate through a number of items.
Company details
| Value | |
|---|---|
| Name | Johnson & Johnson |
| Ticker | JNJ |
| CIK | 0000200406 |
| Exchange | NYSE |
| State | New Jersey |
| Incorporation | New Jersey |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
Fiscal period
| FY2026 | |
|---|---|
| Fiscal year | 2026 |
| Fiscal period | Q2 |
| Tag | FY26Q2 |
| Period end | 2026-06-28 |
| Form | 10-Q |
| Accession | 0000200406-26-000153 |
| Fiscal year end | 0103 |
| Source | facts |
FAQ · Johnson & Johnson financial statements
How much revenue did Johnson & Johnson report in Q2 FY2026?
Johnson & Johnson reported $25.31 billion in sales for Q2 FY2026, the quarter ended June 28, 2026. That is up 6.6% from $23.74 billion in the same quarter a year earlier, and a quarterly sales record for the company.
What were Johnson & Johnson's earnings and EPS in Q2 FY2026?
Johnson & Johnson earned $5.53 billion in Q2 FY2026, down 0.1% from $5.54 billion a year earlier, with diluted EPS of $2.27 against $2.29. Earnings were flat on higher sales because the effective tax rate rose and the quarter carried a new supply chain restructuring charge, Orthopaedics separation costs and higher litigation expense.
How did Johnson & Johnson's Innovative Medicine and MedTech segments perform in Q2 FY2026?
Innovative Medicine sold $16.38 billion to customers in Q2 FY2026, up 7.8% from $15.20 billion, and MedTech sold $8.93 billion, up 4.5% from $8.54 billion. Innovative Medicine remains the larger of Johnson & Johnson's two segments, where oncology growth and TREMFYA's expansion in immunology outweighed the continuing STELARA biosimilar decline.
Why did Johnson & Johnson's profit not grow with sales in Q2 FY2026?
Johnson & Johnson's sales reached $25.31 billion in Q2 FY2026, up 6.6% from a year earlier, while net income of $5.53 billion was little changed from $5.54 billion. The quarter carried a higher effective tax rate than a year earlier, a newly initiated supply chain restructuring program, costs of the planned Orthopaedics separation and higher litigation expense.
Where can I get Johnson & Johnson (JNJ) financial data in machine-readable form?
Ticker Scout publishes Johnson & Johnson's financial statements as JSON at https://tickerscout.ai/jnj/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/jnj/narrative.md and https://tickerscout.ai/jnj/events.md. Johnson & Johnson's SEC CIK is 0000200406. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Johnson & Johnson (JNJ) next file with the SEC?
Johnson & Johnson (JNJ) is expected to file its next Form 10-Q with the SEC on or around October 21, 2026. That date is a projection rather than a company-announced date: it is derived from Johnson & Johnson's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-28, SEC accession 0000200406-26-000153.
Related companies
How this page was built
This page was built from three of Johnson & Johnson's own filings with the SEC, read one at a time. Nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names six such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from Johnson & Johnson's SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.